Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
11 Dec 2017
Change (% chg)

$0.03 (+4.15%)
Prev Close
$0.63
Open
$0.66
Day's High
$0.68
Day's Low
$0.64
Volume
58,148
Avg. Vol
70,625
52-wk High
$1.77
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​
Monday, 13 Nov 2017 07:05am EST 

Nov 13 (Reuters) - Rxi Pharmaceuticals Corp :RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​.RXi Pharmaceuticals - ‍collaborative research agreement to evaluate potential of RXi's sd-rxRNA technology platform for use in cancer treatments​.  Full Article

RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - RXi Pharmaceuticals Corp ::Reports third quarter 2017 financial results and recent corporate highlights.At September 30, 2017, company had cash of $5.4 million, compared with $12.9 million at December 31, 2016​.Qtrly loss per share $0.11​.  Full Article

RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc
Wednesday, 12 Oct 2016 07:02am EDT 

RXi Pharmaceuticals Corp : RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc . RXi Pharmaceuticals Corp - can exercise option to acquire Mirimmune on terms set forth in option agreement at any time prior to April 5, 2017 . RXi Pharmaceuticals Corp - deal for number of shares equal to 19.99% of then outstanding shares of common stock of RXi . RXi Pharmaceuticals Corp - entered into an option agreement to acquire all outstanding capital stock of Mirimmune Inc .RXi Pharmaceuticals Corp - deal also provides for additional potential consideration contingent on Mirimmune reaching certain milestones.  Full Article

RXI Pharmaceuticals Qtrly loss per share $0.34
Thursday, 11 Aug 2016 07:02am EDT 

RXI Pharmaceuticals Corp : RXI Pharmaceuticals reports second quarter 2016 financial results and highlights recent corporate developments .Net revenue for quarter ended june 30, 2016 was $9,000 as compared with no revenues for quarter ended june 30, 2015.  Full Article

Rxi Pharmaceuticals reports Q1 loss of $0.34 per share
Thursday, 12 May 2016 07:40am EDT 

Rxi Pharmaceuticals Corp : Qtrly loss per share $0.34 . Believes existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year .Rxi pharmaceuticals reports first quarter 2016 financial results and highlights recent corporate developments.  Full Article

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS